Synthetic organic

InformationBozitinib (PLB-1001) Bozitinib (PLB-1001, CBT-101, APL-101, CBI-3103) is a highly selective ATP-competitive c-Met inhibitor with blood-brain barrier permeability. Bozitinib (PLB-1001) selectively inhibits MET-altered tumor cells in

InformationBP 897 is a potent and selective agonist of dopamine D3 receptor and a weak antagonist of dopamine D2 receptor with Ki of 0.92 nM and 61 nM for D3 and D2 receptors, respectively. BP 897 shows low affinities at D1 and D4 receptors with Ki

InformationBP 897 is a potent and selective agonist of dopamine D3 receptor and a weak antagonist of dopamine D2 receptor with Ki of 0.92 nM and 61 nM for D3 and D2 receptors, respectively. BP 897 shows low affinities at D1 and D4 receptors with Ki

InformationBP 897 is a potent and selective agonist of dopamine D3 receptor and a weak antagonist of dopamine D2 receptor with Ki of 0.92 nM and 61 nM for D3 and D2 receptors, respectively. BP 897 shows low affinities at D1 and D4 receptors with Ki

InformationBP 897 is a potent and selective agonist of dopamine D3 receptor and a weak antagonist of dopamine D2 receptor with Ki of 0.92 nM and 61 nM for D3 and D2 receptors, respectively. BP 897 shows low affinities at D1 and D4 receptors with Ki

InformationBP 897 is a potent and selective agonist of dopamine D3 receptor and a weak antagonist of dopamine D2 receptor with Ki of 0.92 nM and 61 nM for D3 and D2 receptors, respectively. BP 897 shows low affinities at D1 and D4 receptors with Ki

BPH-252.

BPH-252.

BPH-608.

BPH-608.

BPH-628.

BPH-628.